Vaccines
–Study also suggests vaccine timing is important in maximizing concentration of antibodies transferred to the baby– Excerpt from the Press Release: PHILADELPHIA, Nov. 9, 2022 /PRNewswire/ –Pregnant people who received one of the mRNA COVID-19 vaccines had 10-fold higher antibody concentrations than those who were naturally infected with SARS-CoV-2, a finding that was also…
Read More
Excerpt from the Press Release: A team of researchers at the University of Washington School of Medicine (UWSM) has been working on a breast cancer vaccine for over the last 20 years. In their recently published study, they finally revealed the results of the phase one human trials of their breast cancer vaccine. A WHO…
Read More
Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster…
Read More
Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also includes circulating BA.4 and BA.5 The study is expected to enroll approximately 100 adults in Canada and…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif., Sept. 12, 2022 /PRNewswire/ — Dynavax Technologies Corporation ( Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, in collaboration with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and supported by the DOD’s Chemical and Biological Defense…
Read More
Multicenter basket trial includes cohorts enrolling patients with colorectal and triple negative breast cancer Trial designed to assess efficacy, safety, and evaluate the relationship between tumor Xerna™ TME Panel biomarker subtype and treatment response Excerpt from the Press Release: WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company…
Read More
— Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 — — Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 — —…
Read More
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC),…
Read More
Novel Means of Leveraging Cellular Therapy to “Teach” Immune System to Seek and Destroy Cancer Excerpt from the Press Release: SAN DIEGO, July 26, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), announced today the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of…
Read More
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., July 21, 2022 /PRNewswire/ — Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced the enrollment of the first participant in a Phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV (respiratory syncytial virus)…
Read More